Nursing Elites

1. A client is taking Amiodarone to treat Atrial Fibrillation. Which of the following findings is a manifestation of Amiodarone toxicity?

• A. Light yellow urine
• B. Report of tinnitus
• C. Productive cough
• D. Blue-gray skin discoloration

Correct answer: D

Rationale: Blue-gray skin discoloration is a common sign of Amiodarone toxicity, known as blue-gray discoloration, which can affect areas like the face, neck, or hands. It is important to monitor for this side effect, as it can be a visible indicator of potential toxicity. Choices A, B, and C are incorrect. Light yellow urine is not typically associated with Amiodarone toxicity. Tinnitus is not a common manifestation of Amiodarone toxicity. A productive cough is not a recognized symptom of Amiodarone toxicity.

2. What should you monitor when administering Clopidogrel to a patient?

• A. Signs of thrombotic thrombocytopenic purpura
• B. Bleeding during therapy
• C. CBC with differential and platelet count
• D. All of the above

Correct answer: D

Rationale: When administering Clopidogrel, it is crucial to monitor for signs of thrombotic thrombocytopenic purpura, bleeding during therapy, and changes in CBC with differential and platelet count. Thrombotic thrombocytopenic purpura is a rare but serious condition associated with Clopidogrel use, characterized by microangiopathic hemolytic anemia, thrombocytopenia, neurological symptoms, fever, and renal dysfunction. Monitoring for signs of thrombotic thrombocytopenic purpura is essential to detect this potentially life-threatening condition early. Monitoring for bleeding helps to assess the risk of hemorrhagic events, a known side effect of Clopidogrel. Additionally, regular monitoring of CBC with differential and platelet count is necessary to evaluate the drug's impact on blood cell counts and detect any abnormalities that may require intervention. Therefore, monitoring all these parameters is vital to ensure patient safety and appropriate management during Clopidogrel therapy.

3. A client is being assessed by a healthcare provider while taking Digoxin to manage heart failure. Which of the following findings is a manifestation of digoxin toxicity?

• A. Bruising
• B. Report of metallic taste
• C. Muscle pain
• D. Report of anorexia

Correct answer: D

Rationale: The correct manifestation of digoxin toxicity is anorexia, not bruising, metallic taste, or muscle pain. Other symptoms of digoxin toxicity include blurred vision, stomach pain, and diarrhea. It is crucial for healthcare providers to promptly identify these signs to prevent severe complications.

4. During an assessment, a male client who has recently started taking Haloperidol is displaying certain symptoms. Which of the following findings should the nurse prioritize in reporting to the provider?

• A. Shuffling gait
• B. Neck spasms
• C. Drowsiness
• D. Impotence

Correct answer: B

Rationale: Neck spasms are indicative of acute dystonia, a serious side effect of Haloperidol that requires urgent intervention. Immediate reporting to the provider is crucial to address this potentially harmful condition and ensure the client's safety. Shuffling gait, drowsiness, and impotence are important to monitor but do not pose the same level of immediate risk as acute dystonia. Acute dystonia can lead to serious complications if not promptly treated, making it the priority in this scenario.

5. A client has a new prescription for Cyanocobalamin (Vitamin B12) injections. Which of the following client statements indicates an understanding of the teaching?

• A. I will need to take this medication for the rest of my life.
• B. I will stop taking the medication when my symptoms improve.
• C. I should take this medication with food.
• D. I will need to avoid green, leafy vegetables while taking this medication.

Correct answer: A

Rationale: The correct answer is A. Clients with pernicious anemia or other causes of vitamin B12 deficiency may need to take cyanocobalamin for life to prevent deficiency. It is a lifelong treatment in many cases to maintain adequate B12 levels. Choice B is incorrect because stopping the medication when symptoms improve may lead to a relapse of the deficiency. Choice C is incorrect as cyanocobalamin injections are usually administered on an empty stomach. Choice D is incorrect as there is no need to avoid green, leafy vegetables while taking cyanocobalamin; in fact, these vegetables are good dietary sources of vitamin B12.

Similar Questions